Bulletin from Bactiguard Holding AB’s (publ) Annual General Meeting
At Bactiguard Holding AB’s (publ) Annual General Meeting (AGM) on 5 May 2023, the following resolutions were made:
The AGM adopted the income statements and balance sheets for 2022 and decided that no dividend for the financial year 2022 will be paid. Retained earnings and the company's result for the year will be carried forward.
The Board of Directors and CEO were discharged from liability for their administration of the company for the financial year 2022.
The AGM resolved that the remuneration until the next AGM shall be paid in an amount of SEK 750 000 respectively to the Chairman of the Board and the deputy Chairman and SEK 400 000 to each of the other Directors. No additional remuneration shall be paid for committee work.
Christian Kinch, Anna Martiling, Magdalena Persson, Jan Ståhlberg and Thomas von Koch were re-elected as board members and Dr Rick Kuntz was elected as new member of the Board. Thomas von Koch was re-elected Chairman of the Board and Christian Kinch was re-elected deputy Chairman of the Board.
Deloitte AB was re-elected by the AGM as auditors for the period until the close of the next AGM and it was resolved that remuneration to the auditors shall be paid according to approved invoices.
The AGM adopted the remuneration report, proposed by the Board.
The AGM resolved, in accordance with the Board's proposal, on the authorization for the Board to decide on a new issue of shares, warrants and / or convertibles.
For more information, please contact:
Carin Jakobson, CFO, mobile: +46 709 651 665
Bactiguard press office +46 8 440 58 80 info@bactiguard.com
About Bactiguard
Bactiguard is a global medtech company with a purpose to prevent infections. We provide safe, cost-effective, and easy-to-use infection prevention technology and solutions across five therapeutic areas – orthopedics, urology, intravascular/critical care, dental, and wound care.
Bactiguard’s unique technology is based on a thin noble metal coating that prevents bacterial adhesion and biofilm formation on medical devices. Bactiguard’s solutions are biocompatible and make a positive impact by decreasing patient suffering, saving lives and healthcare resources. The solutions also fight antimicrobial resistance, one of the most serious threats to global health and modern medicine.
Bactiguard operates through license partnerships with leading global medtech companies, such as BD and Zimmer Biomet, differentiating their medical devices with our coating technology, and through the Bactiguard Infection Protection (BIP) product portfolio. BIP includes coated medical devices such as catheters and trauma implants, and wound care products and sutures.
Bactiguard is headquartered in Stockholm, has production in Sweden and Malaysia, and in total around 210 employees. Listed on Nasdaq Stockholm, the company reported revenues of 253.5 MSEK in 2022.
Read more on www.bactiguard.com
Follow Bactiguard on LinkedIn